WMSA
AKBA icon

Weiss Multi-Strategy Advisers’s Akebia Therapeutics AKBA Stock Holding History

Weiss Multi-Strategy Advisers’s Portfolio AKBA Stock Details AKBA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-14,234
Closed -$142K – 509
2018
Q2 		$142K Buy
14,234
+1,234
+9% +$12.4K ﹤0.01% 525
2018
Q1 		$124K Buy
+13,000
New +$182K ﹤0.01% 510

Other funds holding AKBA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Weiss Multi-Strategy Advisers's AKBA Position: Q3 2018 in Review

Weiss Multi-Strategy Advisers sold out of Akebia Therapeutics (AKBA) in Q3 2018, closing a stake of 14,234 shares — an estimated $142K sold.

Weiss Multi-Strategy Advisers first reported a position in AKBA in Q1 2018 and held it in 2 quarters. The position peaked at $142K in Q2 2018. 130 funds tracked by Wall St. Rank hold AKBA as of Q3 2018.

  • Weiss Multi-Strategy Advisers reported no remaining Akebia Therapeutics position as of Q3 2018 after selling out during the quarter.
  • Weiss Multi-Strategy Advisers sold 14,234 Akebia Therapeutics shares in Q3 2018, an estimated $142K.
  • Weiss Multi-Strategy Advisers first reported a position in Akebia Therapeutics in Q1 2018 and held it in 2 quarters.
  • Weiss Multi-Strategy Advisers's Akebia Therapeutics position peaked at $142K in Q2 2018.
  • 130 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q3 2018.

Based on Weiss Multi-Strategy Advisers's 13F filing for Q3 2018, filed 14 Nov 2018.